Skip to main content

Temporal MORE (Modified Orbicularis REpositioning) for correction of lower eyelid displacement following cosmetic blepharoplasty: a prospective study on 117 patients.

Plastic and reconstructive surgery2025-12-09PubMed
Total: 68.5Innovation: 7Impact: 7Rigor: 7Citation: 6

Summary

In 117 patients with post-blepharoplasty lower eyelid displacement, Temporal MORE with lateral canthal tightening and lower lid fat grafting markedly improved ocular symptoms and produced high patient and surgeon cosmetic ratings, with low complication rates. The approach targets anterior lamella deficiency and supports a structured revision strategy.

Key Findings

  • Prospective cohort of 117 patients (2021–2023) with bilateral lower eyelid displacement post-blepharoplasty
  • Patient ocular symptom score improved from 74.91 to 9.03/100; cosmetic satisfaction 53.67/60
  • Surgeon ratings of cosmetic change averaged 51.97/60 based on pre/post photographs by 5 independent surgeons
  • Low complication rates: mild chemosis 5.13%, hypertrophic temporal scar 2.56%, transient frontal nerve palsy 1.71%, hematoma 0.85%; 2 asymmetries and 2 relapses

Clinical Implications

For anterior lamella-driven lower eyelid malposition after blepharoplasty, consider Temporal MORE with lateral canthal tightening and fat grafting; anticipate high satisfaction and low complication risk when executed in experienced hands.

Why It Matters

Addresses a high-anxiety complication in aesthetic eyelid surgery with prospectively collected outcomes and multi-rater assessments, offering a reproducible revision pathway.

Limitations

  • No control or comparator technique; potential confounding by combined procedures
  • Follow-up duration and durability of correction not detailed in the abstract

Future Directions

Comparative studies against alternative revision strategies stratified by lamellar involvement; longer-term outcomes including eyelid position stability and ocular surface health.

Study Information

Study Type
Cohort
Research Domain
Treatment
Evidence Level
III - Prospective single-arm cohort without a control group.
Study Design
OTHER